Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.55 |
| ▸ | CASP2 | P42575 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21572002 | 0.93 | GLP1R (0.54) | GLP1RCASP2SIRT2FAAHNOD1 | |
| SCHEMBL24092197 | 0.92 | GLP1R (0.55) | GLP1RCASP2SIRT2FAAHNOD1 | |
| SCHEMBL20936259 | 0.92 | GLP1R (0.50) | GLP1REPHX2 | |
| SCHEMBL20936257 | 0.92 | GLP1R (0.50) | GLP1REPHX2 | |
| SCHEMBL19057814 | 0.89 | GLP1R (0.51) | GLP1RCASP2SIRT2FAAHNOD1 | |
| SCHEMBL20936258 | 0.85 | GLP1R (0.62) | GLP1RNOD1 | |
| SCHEMBL19057815 | 0.84 | GLP1R (0.66) | GLP1RNOD1EPHX2 | |
| SCHEMBL23552462 | 0.84 | GLP1R (0.66) | GLP1RNOD1EPHX2 | |
| SCHEMBL23552373 | 0.83 | GLP1R (0.51) | GLP1RCASP2SIRT2FAAHNOD1 | |
| SCHEMBL21572000 | 0.82 | GLP1R (0.48) | GLP1REPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11197914-B2 | GLP-1R/GCGR dual target agonist polypeptide for treatment of fatty liver diseases, hyperlipemia and arteriosclerosis | SHENZHEN TURIER BIOTECH CO. LTD. | 2021-12-14 | — | — | US | disclosed |
| US-20190117737-A1 | GLP-1R/GCGR DUAL TARGET AGONIST POLYPEPTIDE FOR TREATMENT OF FATTY LIVER DISEASES, HYPERLIPEMIA AND ARTERIOSCLEROSIS | SHENZHEN TURIER BIOTECH CO., LTD. (CN) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117737-A1 | GLP-1R/GCGR DUAL TARGET AGONIST POLYPEPTIDE FOR TREATMENT OF FATTY LIVER DISEASES, HYPERLIPEMIA AND ARTERIOSCLEROSIS | GLP1R, GCGR, GIPR | GLP1R 1/4885CASP2 411/4885SIRT2 2408/4885 |
| US-11197914-B2 | GLP-1R/GCGR dual target agonist polypeptide for treatment of fatty liver diseases, hyperlipemia and arteriosclerosis | GLP1R, GCGR, GIPR | GLP1R 1/4885CASP2 411/4885SIRT2 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.